Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Latest data show Lynparza's survival benefit in breast cancer

June 5, 2017 10:39 PM UTC

New data from the Phase III OlympiAD trial to treat breast cancer showed that PARP inhibitor Lynparza olaparib from AstraZeneca plc (LSE:AZN; NYSE:AZN) reduced the risk of disease progression or death by 42% compared with chemotherapy (HR=0.58; 95% CI: 0.43, 0.8; p=0.0009). Median progression-free survival (PFS) was 7 months for Lynparza vs. 4.2 months for chemotherapy.

AZ previously said Lynparza met OlympiAD's primary PFS endpoint. Data were presented at the American Society of Clinical Oncology meeting in Chicago (see BioCentury Extra, Feb. 17)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article